VERADIGM INC (MDRX)
(Delayed Data from OTC)
$7.89 USD
-0.14 (-1.74%)
Updated Apr 25, 2024 01:15 PM ET
3-Hold of 5 3
A Value D Growth F Momentum C VGM
Price, Consensus and EPS Surprise
MDRX 7.89 -0.14(-1.74%)
Will MDRX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MDRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MDRX
Veradigm (MDRX) to Acquire AI Service Provider ScienceIO
Veradigm (MDRX) & MedAllies Partner for Better Care Decisions
MDRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Veradigm's (MDRX) Acquires Koha Health to Solidify Market Presence
Braze, Inc. (BRZE) Reports Q3 Loss, Tops Revenue Estimates
Veradigm's (MDRX) New Offering to Enhance Patient Engagement
Other News for MDRX
Teramind Announces Formation of Insider Risk Executive Advisory Board
Veradigm Network Solution Practice Fusion EHR Receives Top Ambulatory Rankings
Veradigm announces strategic collaboration with Vim
Veradigm just downgraded at Deutsche Bank, here's why
Veradigm’s Challenging Outlook: Hold Rating Justified Amid Revenue Growth, Margin Pressures, and Audit Concerns